Immunocore Holdings PLC, a commercial-stage biotechnology company, utilizes its ImmTAX platform to advance a diverse pipeline across various therapeutic areas. These include clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs spanning three therapeutic areas. The company’s lead product, KIMMTRAK, targets unresectable or metastatic uveal melanoma (mUM), […]